Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
REGN
REGN
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
REGN News
Regeneron Recommends Maftivimab for Ebola Treatment Trials
1d ago
Yahoo Finance
WHO Recommends Maftivimab for Ebola Treatment Evaluation
1d ago
NASDAQ.COM
WHO Approves Evaluation of Regeneron's Antibody for Ebola Treatment
1d ago
seekingalpha
Commvault and Others Under Shareholder Investigation
3d ago
Globenewswire
Multiple Companies Under Shareholder Investigation
4d ago
Globenewswire
Regeneron Enters $2.32 Billion Collaboration with Parabilis for Undruggable Proteins
4d ago
Yahoo Finance
Biotech Sector Regulatory Approvals and Collaborations
May 22 2026
NASDAQ.COM
Regeneron Reports Positive Phase 1/2 Results for Lynozyfic in AL Amyloidosis Treatment
May 22 2026
NASDAQ.COM
Regeneron's Otarmeni Accepted for EU Accelerated Review
May 22 2026
NASDAQ.COM
Regeneron Receives EMA Accelerated Review for Otarmeni
May 22 2026
Newsfilter
Regeneron's Lynozyfic Trial Shows Promising Results in AL Amyloidosis
May 22 2026
NASDAQ.COM
Pomerantz LLP Investigates Regeneron for Securities Fraud
May 21 2026
PRnewswire
Regeneron Reports Positive LINKER-AL2 Trial Results for Lynozyfic
May 21 2026
Newsfilter
Parabilis Medicines Files for IPO After $2.3B Deal with Regeneron
May 20 2026
seekingalpha
ETF Analysis: FDG Implies 19.53% Upside Potential
May 20 2026
NASDAQ.COM
Analysis of IBB ETF Trading Dynamics
May 19 2026
NASDAQ.COM
Show More News
